Vitamin E is essential for neuromuscular function. The primary treatment, oral supplementation with natural (‘RRR’) α‐tocopherol, is not effective in all horses. The objectives of this pilot study were to evaluate the safety and efficacy of a subcutaneously administered RRR‐α‐tocopherol preparation. Horses were randomly assigned in a cross‐over design to initially receive RRR‐α‐tocopherol (5000 IU/450 kg of 600 IU/mL) subcutaneously (n = 3) or orally (n = 3) or were untreated sentinels (n = 2). Tissue reactions following injection in Phase I of the study necessitated adjustment of the preparation with reduction of the RRR‐α‐tocopherol concentration to 500 IU/mL in Phase 2. Following an 8‐week washout period, horses received the reciprocal treatment route with the new preparation (5000 IU/450 kg of 500 IU/mL). Serum, CSF and muscle α‐tocopherol concentrations were determined by high‐performance liquid chromatography over a 14‐day period during each phase. Serum and CSF α‐tocopherol concentrations increased significantly postinjection only when the 500 IU/mL product was administered (P<0.0001). There was no significant difference in the muscle concentration of α‐tocopherol following either treatment. All eight horses had marked tissue reaction to subcutaneous injection, regardless of product concentration. Whilst we have demonstrated that this route may be a useful alternative to oral supplementation, the marked tissue reaction makes use of such products limited at this time to only the most refractory of cases.

中文翻译：

---

皮下注射α-生育酚对健康成年马的安全性和有效性

维生素 E 对神经肌肉功能至关重要。主要的治疗方法是口服补充天然 ('RRR') α-生育酚，并非对所有马都有效。这项初步研究的目的是评估皮下给药的 RRR-α-生育酚制剂的安全性和有效性。马被随机分配在交叉设计中，最初接受 RRR-α-生育酚（5000 IU/450 kg 的 600 IU/mL）皮下（n = 3）或口服（n = 3）或未经治疗的哨兵（n = 2）。在研究的第一阶段注射后的组织反应需要调整制剂，在第二阶段将 RRR-α-生育酚浓度降低至 500 IU/mL。在 8 周的冲洗期后，马接受了与新制剂（5000 IU/450 kg 的 500 IU/mL）。血清，脑脊液和肌肉α-生育酚浓度通过高效液相色谱法在每个阶段的 14 天内测定。仅当给予 500 IU/mL 产品时，血清和 CSF α-生育酚浓度在注射后显着增加（P<0.0001）。两种治疗后α-生育酚的肌肉浓度没有显着差异。无论产品浓度如何，所有八匹马都对皮下注射有明显的组织反应。虽然我们已经证明这种途径可能是口服补充剂的有用替代方案，但显着的组织反应使得此类产品的使用目前仅限于最难治的病例。仅当给予 500 IU/mL 产品时，血清和 CSF α-生育酚浓度在注射后显着增加（P<0.0001）。两种治疗后α-生育酚的肌肉浓度没有显着差异。无论产品浓度如何，所有八匹马都对皮下注射有明显的组织反应。虽然我们已经证明这种途径可能是口服补充剂的有用替代方案，但显着的组织反应使得此类产品的使用目前仅限于最难治的病例。仅当给予 500 IU/mL 产品时，血清和 CSF α-生育酚浓度在注射后显着增加（P<0.0001）。两种治疗后α-生育酚的肌肉浓度没有显着差异。无论产品浓度如何，所有八匹马都对皮下注射有明显的组织反应。虽然我们已经证明这种途径可能是口服补充剂的有用替代方案，但显着的组织反应使得此类产品的使用目前仅限于最难治的病例。与产品浓度无关。虽然我们已经证明这种途径可能是口服补充剂的有用替代方案，但显着的组织反应使得此类产品的使用目前仅限于最难治的病例。与产品浓度无关。虽然我们已经证明这种途径可能是口服补充剂的有用替代方案，但显着的组织反应使得此类产品的使用目前仅限于最难治的病例。